Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer.
Carmine ConteClaudia MarchettiMatteo LoverroMaria Teresa GiudiceAndrea RosatiValerio GallottaGiovanni ScambiaAnna FagottiPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023)
Patients with single or oligometastatic recurrences can be offered minimally invasive secondary cytoreductive surgery, mainly if localized in the lymph-nodes, and/or if they received neoadjuvant chemotherapy at primary diagnosis. Minimally invasive secondary cytoreductive surgery is associated with favorable perioperative outcomes with no differences in terms of post-recurrence survival with respect to open approach.
Keyphrases
- minimally invasive
- neoadjuvant chemotherapy
- lymph node
- robot assisted
- sentinel lymph node
- locally advanced
- free survival
- cardiac surgery
- patients undergoing
- type diabetes
- squamous cell carcinoma
- metastatic renal cell carcinoma
- metabolic syndrome
- adipose tissue
- coronary artery disease
- skeletal muscle
- acute kidney injury
- percutaneous coronary intervention